RARE DISEASE
Rare head and neck tumor
Rare head and neck tumor
Rare head and neck tumor
Drug discovery
4
drugs
With orphan designations
Overview
Rare head and neck tumors (R-HNCs) encompass diverse malignancies such as salivary gland cancers, sinonasal tumors, mucosal melanomas, neuroendocrine neoplasms, and sarcomas. These tumors represent <5% of all head and neck cancers and pose diagnostic challenges due to histological heterogeneity and overlapping features with common subtypes. Management requires specialized molecular profiling, multidisciplinary collaboration, and tailored therapies addressing unique molecular drivers [1][6][14].
Population
Annual incidence ranges from 0.26–48 cases per million depending on subtype (e.g., 13/million for salivary gland tumors vs <5/million for nasal/paranasal cancers) [1][15]
Higher nasopharyngeal cancer rates in Asian populations vs sinonasal tumors in Europe [6][9]
Pediatric rhabdomyosarcoma accounts for 3% of childhood cancers, with median diagnosis at age 10 [5]
Burden
Global incidence increased by 35% from 1990–2019, with highest DALYs in Asia [4]
5-year survival ranges from 17% (metastatic rhabdomyosarcoma) to 90% (early-stage nasopharyngeal cancer) [5][19]
Significant treatment-related morbidity: 60% of patients develop chronic dysphagia or voice impairment post-chemoradiation [3][14]
Categories: rare neoplastic diseases
Research Papers
206 drug discovery papers about Rare head and neck tumor, with 1 first-in-class and 1 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
206 drug discovery papers about Rare head and neck tumor, with 1 first-in-class and 1 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-06-22 | Integrating Immunotherapy Into Head and Neck Surgery: Bridging Tumor Biology to Perioperative Decision‐Making, a Review
OBJECTIVE: To provide a comprehensive review of the biological rationale, clinical evidence, and practical perioperative management of immunotherapy for the head and neck surgeon. SUMMARY BACKGROUND DATA: Standard treatment for resectable head and neck squamous cell carcinoma (HNSCC) has reached a survival plateau, with over 50% of patients experiencing recurrence. The integration of immune checkpoint inhibitors (ICIs) into the neoadjuvant window represents a paradigm shift toward biologically adapted surgical intervention. RESULTS: Neoadjuvant immunotherapy capitalizes on an intact immune substrate to create an in situ vaccine, avoiding the post-surgical immune desert that limits adjuvant efficacy. Emerging phase III data confirm that perioperative ICI significantly improves event-free survival. Successful implementation requires the surgeon to navigate unique diagnostic challenges, such as distinguishing rare but anatomically risky pseudoprogression from true progression. While combination therapies (chemoimmunotherapy or immunoradiotherapy) yield higher pathologic complete response rates, they also increase toxicity. Intraoperatively, ICI monotherapy generally preserves tissue planes without increasing surgical delays or major wound complications. Standard biomarkers like PD-L1 and TMB, alongside emerging tools such as liquid biopsy (ctDNA), are essential for patient selection and dynamic monitoring. CONCLUSIONS: The transition to neoadjuvant immunotherapy facilitates future surgical de-escalation and function-preserving approaches. To optimize outcomes, the modern surgeon must act as a surgical immunologist, interpreting translational data to guide real-time operative planning.
2026-06-01 | Advances in Systemic Therapies for Rare Head and Neck Malignancies: Spotlight on Adenoid Cystic Carcinoma, Differentiated Thyroid Cancer, and Sinonasal/Paranasal Tumors
Rare head and neck cancers, including adenoid cystic carcinoma (ACC), differentiated thyroid cancer (DTC), and sinonasal/paranasal tumors, represent a diverse pathology with shared clinical challenges, including heterogenous biology and limited prospective evidence. Although these tumors may present commonly as locally aggressive disease, there is distant metastatic potential, underscoring the complexities of treatment selection. Precision medicine has broadened the landscape of treatment modalities for these rare tumors; nevertheless, there are persistent critical needs for more robust molecular predictors to refine risk stratification, enhance prognostic accuracy, and drive innovative targeted therapies. In ACC, multikinase inhibitors remain a central systemic therapy strategy; however, emerging options targeting MYB and NOTCH pathways, theranostics by prostate-specific membrane antigen‑directed radioligand therapy, and immunotherapy are providing novel alternatives of care for patients with these malignancies. In radioactive iodine‑refractory DTC, redifferentiation approaches using an antineoplastic agent for 4-6 weeks have restored I131 uptake in selected patients. Clinical trials and real-world experiences with BRAF, MEK, RET, and NTRK inhibitors have revealed that a subset of patients may benefit from this approach to delay long-term systemic therapy initiation. Molecular testing has enabled better classification of sinonasal tumors, in which multimodal therapeutic approaches have been the cornerstone, with newer biomarkers guiding the consideration of immunotherapy implementation among other alternatives. In these rare malignancies, patient-centered care, including timely access to expert multidisciplinary teams in high-volume centers, prioritization for clinical trial enrollment, and balancing options on the basis of molecular profiles, remains essential to advance the field.
2026-05-14 | Endovascular embolization in the treatment of patients with complicated malignant neoplasms of the head and neck organs
Malignant neoplasms of the head and neck organs are quite rare, but they are the leading causes of death in cancer patients. High mortality rates are associated with the peculiarities of the clinical course of tumors of this localization, their pronounced effect on the patient’s somatic status, as well as the highly toxic methods of antitumor treatment used. Due to the unique topographic and anatomical features of the structures of the head and neck, malignant tumors in the process of their growth can give a wide range of complications, significantly aggravating the clinical prognosis. Bleeding in the head and neck prevents the initiation or continuation of antitumor treatment, and in some cases is the reason for its complete rejection. The main method of hemostasis in such situations for a long time was open ligation of the branches of the external carotid artery or its trunk, which often led to the development of irreversible ischemic disorders and frequent recurrence of bleeding due to the opening of collateral blood flow. These disadvantages required the development and widespread implementation of new methods of hemostasis, which make it possible to stop bleeding in cancer patients with a lower risk of complications. Vascular embolization is used as one of these methods today. The purpose of this work is to review the scientific literature data on the methodology of vascular embolization of tumors of the head and neck, modern devices used for endovascular embolization and embolizing agents, complications of intraarterial embolization of tumor vessels during tumor bleeding, as well as the clinical significance of this method in the treatment of complications of the course of the tumor process in the head and neck.
2026-04-14 | The Molecular Landscape of CASTLE: A Rare Thymus-like Head and Neck Cancer
Carcinoma showing thymus-like differentiation (CASTLE) is a rare malignancy arising in the thyroid or neck, with an uncertain cellular origin that complicates both diagnosis and treatment. To better understand its molecular underpinnings and identify potential therapeutic avenues, we conducted integrated whole-exome and transcriptome sequencing on six CASTLE and six thymic carcinoma samples. Whole-exome sequencing (WES) was performed on all 12 samples, while RNA sequencing was successful for 1 CASTLE and 6 thymic carcinoma samples. Our analysis included somatic mutation profiling, mutational signature deconvolution, differential gene expression, and characterization of tumor microenvironment for the cases with available data, with comparisons to genomic data from other thyroid cancers. CASTLE tumors demonstrated a higher median tumor mutational burden than thymic carcinoma and lacked the common BRAF and RAS mutations typically found in thyroid cancers. They harbored alterations in genes such as TRHDE, cilia-associated genes (ANKS6, CFAP46, DNAH6), and Wnt signaling components (TRRAP, BCL9L), as well as mutational signatures suggestive of mismatch repair deficiency and oxidative damage. MSIsensor-pro analysis of the WES data provided support for the potential for mismatch repair deficiency in a subset of CASTLE samples. Exploratory transcriptomic analysis from a single CASTLE case showed downregulation of thyroid follicular markers and an “immune-hot”, lymphocyte-rich microenvironment, closely resembling that of thymic carcinoma. While these findings require validation in larger cohorts, they support a thymic origin for CASTLE and establish its molecular distinction from follicular-derived thyroid cancers. The immunogenic tumor landscape suggests that immune checkpoint inhibitors, particularly those targeting PD-1/PD-L1, may be a promising therapeutic strategy, alongside emerging targets for precision oncology.
2026-03-19 | Rare Presentation of Myxoid Pleomorphic Liposarcoma in Cervical Prevertebral Region
Myxoid pleomorphic liposarcoma (MPLS) is a rare subtype of liposarcoma, with the mediastinum being the most common site.Prevalence in the head and neck region is extremely rare.These tumors are very aggressive due to the presence of TP53 mutation and widespread loss of heterozygosity (LOH).These tumors are usually asymptomatic and therefore diagnosed at advanced stages.Surgery followed by adjuvant chemoradiation remains the mainstay of treatment.We report a case of MPLS at a very rare location, the cervical prevertebral region (C4-D3).
2026-06-22 | Integrating Immunotherapy Into Head and Neck Surgery: Bridging Tumor Biology to Perioperative Decision‐Making, a Review
OBJECTIVE: To provide a comprehensive review of the biological rationale, clinical evidence, and practical perioperative management of immunotherapy for the head and neck surgeon. SUMMARY BACKGROUND DATA: Standard treatment for resectable head and neck squamous cell carcinoma (HNSCC) has reached a survival plateau, with over 50% of patients experiencing recurrence. The integration of immune checkpoint inhibitors (ICIs) into the neoadjuvant window represents a paradigm shift toward biologically adapted surgical intervention. RESULTS: Neoadjuvant immunotherapy capitalizes on an intact immune substrate to create an in situ vaccine, avoiding the post-surgical immune desert that limits adjuvant efficacy. Emerging phase III data confirm that perioperative ICI significantly improves event-free survival. Successful implementation requires the surgeon to navigate unique diagnostic challenges, such as distinguishing rare but anatomically risky pseudoprogression from true progression. While combination therapies (chemoimmunotherapy or immunoradiotherapy) yield higher pathologic complete response rates, they also increase toxicity. Intraoperatively, ICI monotherapy generally preserves tissue planes without increasing surgical delays or major wound complications. Standard biomarkers like PD-L1 and TMB, alongside emerging tools such as liquid biopsy (ctDNA), are essential for patient selection and dynamic monitoring. CONCLUSIONS: The transition to neoadjuvant immunotherapy facilitates future surgical de-escalation and function-preserving approaches. To optimize outcomes, the modern surgeon must act as a surgical immunologist, interpreting translational data to guide real-time operative planning.
2026-06-01 | Advances in Systemic Therapies for Rare Head and Neck Malignancies: Spotlight on Adenoid Cystic Carcinoma, Differentiated Thyroid Cancer, and Sinonasal/Paranasal Tumors
Rare head and neck cancers, including adenoid cystic carcinoma (ACC), differentiated thyroid cancer (DTC), and sinonasal/paranasal tumors, represent a diverse pathology with shared clinical challenges, including heterogenous biology and limited prospective evidence. Although these tumors may present commonly as locally aggressive disease, there is distant metastatic potential, underscoring the complexities of treatment selection. Precision medicine has broadened the landscape of treatment modalities for these rare tumors; nevertheless, there are persistent critical needs for more robust molecular predictors to refine risk stratification, enhance prognostic accuracy, and drive innovative targeted therapies. In ACC, multikinase inhibitors remain a central systemic therapy strategy; however, emerging options targeting MYB and NOTCH pathways, theranostics by prostate-specific membrane antigen‑directed radioligand therapy, and immunotherapy are providing novel alternatives of care for patients with these malignancies. In radioactive iodine‑refractory DTC, redifferentiation approaches using an antineoplastic agent for 4-6 weeks have restored I131 uptake in selected patients. Clinical trials and real-world experiences with BRAF, MEK, RET, and NTRK inhibitors have revealed that a subset of patients may benefit from this approach to delay long-term systemic therapy initiation. Molecular testing has enabled better classification of sinonasal tumors, in which multimodal therapeutic approaches have been the cornerstone, with newer biomarkers guiding the consideration of immunotherapy implementation among other alternatives. In these rare malignancies, patient-centered care, including timely access to expert multidisciplinary teams in high-volume centers, prioritization for clinical trial enrollment, and balancing options on the basis of molecular profiles, remains essential to advance the field.
2026-05-14 | Endovascular embolization in the treatment of patients with complicated malignant neoplasms of the head and neck organs
Malignant neoplasms of the head and neck organs are quite rare, but they are the leading causes of death in cancer patients. High mortality rates are associated with the peculiarities of the clinical course of tumors of this localization, their pronounced effect on the patient’s somatic status, as well as the highly toxic methods of antitumor treatment used. Due to the unique topographic and anatomical features of the structures of the head and neck, malignant tumors in the process of their growth can give a wide range of complications, significantly aggravating the clinical prognosis. Bleeding in the head and neck prevents the initiation or continuation of antitumor treatment, and in some cases is the reason for its complete rejection. The main method of hemostasis in such situations for a long time was open ligation of the branches of the external carotid artery or its trunk, which often led to the development of irreversible ischemic disorders and frequent recurrence of bleeding due to the opening of collateral blood flow. These disadvantages required the development and widespread implementation of new methods of hemostasis, which make it possible to stop bleeding in cancer patients with a lower risk of complications. Vascular embolization is used as one of these methods today. The purpose of this work is to review the scientific literature data on the methodology of vascular embolization of tumors of the head and neck, modern devices used for endovascular embolization and embolizing agents, complications of intraarterial embolization of tumor vessels during tumor bleeding, as well as the clinical significance of this method in the treatment of complications of the course of the tumor process in the head and neck.
2026-04-14 | The Molecular Landscape of CASTLE: A Rare Thymus-like Head and Neck Cancer
Carcinoma showing thymus-like differentiation (CASTLE) is a rare malignancy arising in the thyroid or neck, with an uncertain cellular origin that complicates both diagnosis and treatment. To better understand its molecular underpinnings and identify potential therapeutic avenues, we conducted integrated whole-exome and transcriptome sequencing on six CASTLE and six thymic carcinoma samples. Whole-exome sequencing (WES) was performed on all 12 samples, while RNA sequencing was successful for 1 CASTLE and 6 thymic carcinoma samples. Our analysis included somatic mutation profiling, mutational signature deconvolution, differential gene expression, and characterization of tumor microenvironment for the cases with available data, with comparisons to genomic data from other thyroid cancers. CASTLE tumors demonstrated a higher median tumor mutational burden than thymic carcinoma and lacked the common BRAF and RAS mutations typically found in thyroid cancers. They harbored alterations in genes such as TRHDE, cilia-associated genes (ANKS6, CFAP46, DNAH6), and Wnt signaling components (TRRAP, BCL9L), as well as mutational signatures suggestive of mismatch repair deficiency and oxidative damage. MSIsensor-pro analysis of the WES data provided support for the potential for mismatch repair deficiency in a subset of CASTLE samples. Exploratory transcriptomic analysis from a single CASTLE case showed downregulation of thyroid follicular markers and an “immune-hot”, lymphocyte-rich microenvironment, closely resembling that of thymic carcinoma. While these findings require validation in larger cohorts, they support a thymic origin for CASTLE and establish its molecular distinction from follicular-derived thyroid cancers. The immunogenic tumor landscape suggests that immune checkpoint inhibitors, particularly those targeting PD-1/PD-L1, may be a promising therapeutic strategy, alongside emerging targets for precision oncology.
2026-03-19 | Rare Presentation of Myxoid Pleomorphic Liposarcoma in Cervical Prevertebral Region
Myxoid pleomorphic liposarcoma (MPLS) is a rare subtype of liposarcoma, with the mediastinum being the most common site.Prevalence in the head and neck region is extremely rare.These tumors are very aggressive due to the presence of TP53 mutation and widespread loss of heterozygosity (LOH).These tumors are usually asymptomatic and therefore diagnosed at advanced stages.Surgery followed by adjuvant chemoradiation remains the mainstay of treatment.We report a case of MPLS at a very rare location, the cervical prevertebral region (C4-D3).
Access all drug discovery papers and probability of success in trials forecasts:
Access all drug discovery papers and probability of success in trials forecasts:
Drug Discovery Landscape
4 orphan drug designations for Rare head and neck tumor.
4 orphan drug designations for Rare head and neck tumor.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Cyclo(arginyl-glycyl-aspartyl-D-tyrosyl-lysyl)-nizaracianine-1 | peptides | EMA | 2026-06-19 | — | Curadel Surgical Innovations B.V. |
Replication defective recombinant adenovirus serotype 5 vector carrying the p53 gene in its E1 deleted region | gene therapies | FDA | 2003-01-27 | — | Introgen Therapeutics, Inc. |
tirapazamine | small molecules | FDA | 2002-10-23 | — | Sanofi-Aventis US, Inc. |
Porfiromycin | small molecules | FDA | 1995-09-19 | — | Boehringer Ingelheim Pharmaceuticals, Inc. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.